Investment
Features
FeesSafety
Academy
More
Pluang+

Anthropic and Nscale in talks for another $45B AI compute deal amid IPO plans

Market News
19 Oct 2026
TechCrunch
View Source
Neutral
Anthropic and Nscale in talks for another $45B AI compute deal amid IPO plans

Anthropic and AI infrastructure provider Nscale are reportedly negotiating a second $45 billion compute deal shortly after their initial agreement. This potential deal highlights the massive investments being made in AI computing power despite investor concerns about profitability. Both companies are also preparing for IPOs, with Anthropic expected to go public this year and Nscale facing some investor resistance over its $30 billion valuation. The outcome of these talks could significantly impact the AI infrastructure market and investor sentiment.

The talks between Nscale and Anthropic on a $45 billion compute deal provide context for readers interested in AI infrastructure investments. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Oct 20, 2026 05:21 WIB: out of 150 stocks, 109 rose and 37 fell. Notable movers include UMC at USD 19.68 with a 1-day change of -5.90% and Pluang order activity showing 55% Sell / 45% Buy, NTAP at USD 202.44 down 5.71% with 86% Sell / 14% Buy, and DDOG at USD 261.00 up 5.62%, with a typical hold time of 77 days.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
53 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
53 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App